|
CILNIDIPINE |
| Atelec; Cinalong; Siscard; (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; O3-(2-Methoxyethyl) O5-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
132203-70-4 |
|
EINECS RN |
|
|
FORMULA |
C27H28N2O7 |
|
MOLE WEIGHT |
492.52 |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
light yellowish powder |
|
MELTING POINT |
107 - 112 C |
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
|
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. Light may affect product. |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents. |
| DECOMPOSITION PRODUCTS | carbon oxides, nitrogen oxides. |
| POLYMERIZATION | Has not been reported |
|
NFPA RATINGS |
Health: 2, Flammability: 0, Reactivity: 0 |
|
|
| SAFETY |
|
|
HAZARD NOTES |
Irritant. Risk of serious damage to eyes. |
|
EYE |
Causes eye irritation. |
|
SKIN |
Causes skin irritation. May be harmful if absorbed through the skin. |
|
INGESTION |
Harmful if swallowed. |
|
INHALATION |
Material is irritating to mucous membranes and upper respiratory tract. May be harmful if inhaled. |
|
CHRONIC |
|
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
|
| HAZARD CLASS |
|
| PACKING GROUP |
|
| HAZARD SYMBOL |
XI |
|
RISK PHRASES |
41 |
|
SAFETY PHRASES |
26-39 |
|
|
| EXTERNAL LINKS & GENERAL INFORMATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
N-Type calcium channel antagonists may suppress sympathetic activity. The
purpose of this study was to assess the effects of amlodipine and cilnidipine on
the cardiac sympathetic nervous system and the neurohormonal status of essential
hypertension. I-metaiodobenzylguanidine (MIBG) cardiac imaging was performed and
blood samples were taken to determine plasma renin activity and plasma
norepinephrine concentration before and 3 months after drug administration in 47
patients with mild essential hypertension. Twenty-four of the patients were
treated with 5 to 10 mg/d of amlodipine; the other 23 were treated with 10 to 20
mg/d of cilnidipine. For comparison, 12 normotensive subjects were also studied.
No significant differences were found in the basal characteristics between the 2
hypertensive groups. In both hypertensive groups, both the systolic and
diastolic blood pressures were significantly reduced to similar levels 3 months
after drug treatment. Before the drug treatment, the 2 hypertensive groups had a
significantly higher washout rate and lower heart-to-mediastinum (H/M) ratio
compared with the normotensive subjects. The H/M ratio significantly increased
(P<0.05) in combination with a decreased washout rate (P<0.02) after drug
treatment in the cilnidipine group. In the amlodipine group, a significant
decrease in washout rate (P<0.04) was noted, without an increase in the H/M
ratio. However, no significant changes were found in plasma renin activity and
plasma norepinephrine concentration in either group. Thus, in patients with
essential hypertension, cilnidipine suppressed cardiac sympathetic overactivity
and amlodipine had a little suppressive effect. Cilnidipine may provide a new
strategy for treatment of cardiovascular diseases with sympathetic overactivity.
( http://hyper.ahajournals.org/)
Calcium channel blockers
|
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
light yellowish powder |
|
ASSAY |
98.0 - 101.0% |
|
MELTING POINT |
107 - 112 C |
|
HEAVY METALS |
20ppm max |
|
LOS ON DRYING |
0.5% max |
|
RESIDUE ON IGNITION |
0.1% max |
